JP2016526558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526558A5 JP2016526558A5 JP2016524294A JP2016524294A JP2016526558A5 JP 2016526558 A5 JP2016526558 A5 JP 2016526558A5 JP 2016524294 A JP2016524294 A JP 2016524294A JP 2016524294 A JP2016524294 A JP 2016524294A JP 2016526558 A5 JP2016526558 A5 JP 2016526558A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- cycloalkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000005549 heteroarylene group Chemical group 0.000 claims 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842321P | 2013-07-02 | 2013-07-02 | |
| US61/842,321 | 2013-07-02 | ||
| PCT/US2014/044922 WO2015002894A1 (en) | 2013-07-02 | 2014-06-30 | Purinone compounds as kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018237711A Division JP2019069977A (ja) | 2013-07-02 | 2018-12-19 | キナーゼ阻害剤としてのプリノン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526558A JP2016526558A (ja) | 2016-09-05 |
| JP2016526558A5 true JP2016526558A5 (enExample) | 2017-07-06 |
| JP6458018B2 JP6458018B2 (ja) | 2019-01-23 |
Family
ID=52144143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524294A Expired - Fee Related JP6458018B2 (ja) | 2013-07-02 | 2014-06-30 | キナーゼ阻害剤としてのプリノン化合物 |
| JP2018237711A Pending JP2019069977A (ja) | 2013-07-02 | 2018-12-19 | キナーゼ阻害剤としてのプリノン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018237711A Pending JP2019069977A (ja) | 2013-07-02 | 2018-12-19 | キナーゼ阻害剤としてのプリノン化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9637487B2 (enExample) |
| EP (1) | EP3016953A4 (enExample) |
| JP (2) | JP6458018B2 (enExample) |
| CA (1) | CA2917167A1 (enExample) |
| WO (1) | WO2015002894A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3812387A1 (en) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| US8501724B1 (en) * | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| MX394360B (es) | 2013-03-14 | 2025-03-24 | Sumitomo Pharma Oncology Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
| WO2015002894A1 (en) * | 2013-07-02 | 2015-01-08 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
| WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
| CN105753863B (zh) * | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| WO2018002958A1 (en) | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
| CN106146518A (zh) * | 2016-06-30 | 2016-11-23 | 苏州爱玛特生物科技有限公司 | 一种布鲁顿酪氨酸激酶抑制剂中间体及其制备方法 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| AU2018224136B2 (en) | 2017-02-24 | 2021-10-21 | Gilead Sciences, Inc. | Inhibitors of Bruton's Tyrosine Kinase |
| US10314844B2 (en) | 2017-02-24 | 2019-06-11 | Gilead Sciences, Inc. | Inhibitors of Bruton's tyrosine kinase |
| AU2018345647A1 (en) * | 2017-10-04 | 2020-04-16 | Celgene Corporation | Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| KR20210003780A (ko) | 2018-04-05 | 2021-01-12 | 스미토모 다이니폰 파마 온콜로지, 인크. | Axl 키나제 억제제 및 그의 용도 |
| JP2021521170A (ja) | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤 |
| AU2019310590A1 (en) | 2018-07-26 | 2021-01-14 | Sumitomo Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| KR20260008165A (ko) | 2019-02-12 | 2026-01-15 | 스미토모 파마 아메리카, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR102409595B1 (ko) * | 2020-06-29 | 2022-06-17 | 한국과학기술연구원 | 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체 |
| TW202220994A (zh) * | 2020-08-17 | 2022-06-01 | 大陸商貝達藥業股份有限公司 | 雙環化合物，包含其的藥物組合物及其用途 |
| CN114573586B (zh) * | 2020-11-28 | 2023-11-03 | 杭州和正医药有限公司 | 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN120302975A (zh) | 2022-10-31 | 2025-07-11 | 住友制药美国公司 | 治疗骨髓增生性肿瘤的pim1抑制剂 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3957023B2 (ja) * | 1997-11-12 | 2007-08-08 | 三菱化学株式会社 | プリン誘導体及びそれを有効成分として含む医薬 |
| CN1130363C (zh) * | 1997-11-12 | 2003-12-10 | 三菱化学株式会社 | 嘌呤衍生物以及含有其作为有效成分的药物 |
| US7071199B1 (en) * | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
| MXPA02002938A (es) * | 1999-09-17 | 2004-12-06 | Abbott Gmbh & Co Kg | Inhibidores de cinasa como agentes agentes terapeuticos. |
| CA2465328C (en) | 2001-11-01 | 2011-06-14 | Michael Francis Gross | Piperidines |
| US20090023723A1 (en) * | 2005-09-21 | 2009-01-22 | Pharmacopeia Drug Discovery, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| US20120101114A1 (en) * | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| SG10202107066WA (en) | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| TWI500617B (zh) * | 2010-05-31 | 2015-09-21 | Ono Pharmaceutical Co | Purine ketone derivatives |
| JP6147727B2 (ja) * | 2011-04-01 | 2017-06-14 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体 |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| US8501724B1 (en) * | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| WO2015002894A1 (en) * | 2013-07-02 | 2015-01-08 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| BR112016006978A2 (pt) | 2013-09-30 | 2017-08-01 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton |
-
2014
- 2014-06-30 WO PCT/US2014/044922 patent/WO2015002894A1/en not_active Ceased
- 2014-06-30 EP EP14819592.8A patent/EP3016953A4/en not_active Withdrawn
- 2014-06-30 JP JP2016524294A patent/JP6458018B2/ja not_active Expired - Fee Related
- 2014-06-30 CA CA2917167A patent/CA2917167A1/en not_active Abandoned
- 2014-06-30 US US14/902,759 patent/US9637487B2/en not_active Expired - Fee Related
-
2017
- 2017-03-22 US US15/466,472 patent/US20180037583A1/en not_active Abandoned
-
2018
- 2018-06-08 US US16/004,062 patent/US20190144451A1/en not_active Abandoned
- 2018-12-19 JP JP2018237711A patent/JP2019069977A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526558A5 (enExample) | ||
| JP2018513150A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2019524883A5 (enExample) | ||
| JP2018529650A5 (enExample) | ||
| JP2015509927A5 (enExample) | ||
| JP2020531422A5 (enExample) | ||
| JP2021513534A5 (enExample) | ||
| JP2019527718A5 (enExample) | ||
| JP2015520140A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| JP2018115201A5 (enExample) | ||
| JP2017523225A5 (enExample) | ||
| JP2018158926A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2013519645A5 (enExample) | ||
| JP2015505296A5 (enExample) | ||
| JP2017523143A5 (enExample) | ||
| JP2012505916A5 (enExample) | ||
| JP2013510120A5 (enExample) | ||
| JP2016519062A5 (enExample) | ||
| JP2015537008A5 (enExample) | ||
| JP2017537066A5 (enExample) | ||
| JP2017504635A5 (enExample) |